Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy

被引：0
作者：
E. Jason Abel
Christopher G. Wood
机构：
[1] University of Texas M. D. Anderson Cancer Center,Department of Urology
来源：
Nature Reviews Urology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The development of targeted therapy for renal cell carcinoma (RCC) has changed the treatment options for patients with metastatic RCC. The authors of this Review discuss the current and future role of cytoreductive nephrectomy in combination with targeted therapies, and the rationale for presurgical therapy for this group of patients.
引用
收藏
页码：375 / 383
页数：8
相关论文
共 146 条
[1]  
Janzen NK(2003)Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol. Clin. North Am. 30 843-852
[2]  
Kim HL(2008)Prognostic models and algorithms in renal cell carcinoma Urol. Clin. North Am. 35 613-625
[3]  
Figlin RA(1993)Cytotoxic chemotherapy for advanced renal cell carcinoma Urol. Clin. North Am. 20 303-321
[4]  
Belldegrun AS(2007)Jr. Renal cell carcinoma: current status and emerging therapies Cancer Treat. Rev. 33 299-313
[5]  
Lane BR(2001)Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N. Engl. J. Med. 345 1655-1659
[6]  
Kattan MW(2001)Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966-970
[7]  
Yagoda A(1993)Identification of the von Hippel–Lindau disease tumor suppressor gene Science 260 1317-1320
[8]  
Petrylak D(1994)Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma Hum. Mol. Genet. 3 2169-2173
[9]  
Thompson S(2004)Role of VHL gene mutation in human cancer J. Clin. Oncol. 22 4991-5004
[10]  
Nelson EC(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 115-124
12345678910